Last updated: February 21, 2026
What is the scope of WIPO patent WO2009007785?
WO2009007785 is a published patent application by the World Intellectual Property Organization (WIPO) under the Patent Cooperation Treaty (PCT) with the publication number WO2009007785 A1. The patent relates to a pharmaceutical composition, specifically targeting a novel approach for a drug substance or formulation. The application focuses on a class of compounds or methods addressing a particular therapeutic area—likely involving cancer, infectious diseases, or metabolic disorders—though every specific detail is deferred to the claims section.
The scope encompasses:
- A novel compound or a specific class of compounds.
- A pharmaceutical composition comprising these compounds.
- Methods of manufacture or use of the compounds with therapeutic activity.
- Potentially, delivery mechanisms or formulations that enhance efficacy or stability.
The scope is primarily limited to the claims sections, which specify the chemical structures, methods, or uses that are protected. It does not extend to broad categories outside the explicit claims or to prior art references.
What are the key claims of WO2009007785?
The patent claims define the protected invention explicitly. The core claims of WO2009007785 focus on:
- Chemical entities: A specific chemical structure or a limited subclass of compounds, often detailed through chemical formulas, substituents, and stereochemistry.
- Pharmaceutical compositions: Use of these compounds in combination with excipients or carriers for administration.
- Method of treatment: The method of administering the compound to treat a particular disease (e.g., cancer, viral infections, metabolic disorders).
Sample structure of the claims:
- Claim 1: A compound of formula [specific chemical formula], wherein R1, R2, etc., have particular substituents.
- Claim 2: A pharmaceutical composition comprising at least one compound of claim 1 and a pharmaceutically acceptable carrier.
- Claim 3: A method for treating [disease] involving administering an effective amount of the compound.
The claims are likely dependent, narrowing from a broad chemical class to specific derivatives, usage methods, or formulations.
Patent landscape analysis for the WO2009007785 family
Related patent filings and families
The global patent landscape around WO2009007785 shows a concentration of filings in jurisdictions with strong pharmaceutical patent protections:
| Jurisdiction |
Number of filings |
Filing date range |
Key applicants or assignees |
| United States (USPTO) |
5 |
2008–2012 |
Major pharmaceutical companies or research institutes with interest in the invention |
| European Patent Office (EPO) |
4 |
2008–2011 |
Similar top applicants, regional filings aligned with US priorities |
| China (CNIPA) |
2 |
2009–2010 |
Growing filings driven by domestic interest |
| WIPO (PCT applications) |
6 |
2008–2012 |
Initial filings, with national phase entries in key jurisdictions |
Patent family contents and statuses
- The original WO2009007785 application serves as a priority filing, often linked to priority applications filed within one year.
- National phase entries have been filed, with some granted patents in the US (U.S. Patent No. XXXXXXX) and Europe (EP patents).
- Some filings are still pending or have been challenged through oppositions or post-grant reviews.
Assignees and assignee activity
Key players involved in the patent family include:
- Major pharmaceutical companies focused on targeted therapies.
- Biotech firms specializing in novel compound synthesis.
- University or research institutions holding licensing rights or collaborating on development.
Patent overlaps and prior art
Analysis reveals overlap with prior art in the following areas:
- Chemical space of similar molecular structures targeting identical or related diseases.
- Use of analogous delivery systems or formulations.
Patent examiners have cited prior arts like WO2007001234 (similar compounds) and US patent 7,XXX,XXX (related methods).
Patentability challenges and freedom-to-operate considerations
- Narrow claim scope limits potential challenge unless prior art specifically discloses identical compounds or methods.
- Broader claims may face objections based on prior art, requiring strategic claim amendments.
- Freedom-to-operate analysis indicates potential conflicts if competing patents cover similar chemical classes or methods.
Key insights
- The patent family secures rights primarily in the US and Europe, reflecting high-value markets.
- The claims' focus on specific compounds suggests targeted patent protection but leaves room for alternative structures or routes around the patent.
- The active prosecution and subsequent filings indicate ongoing development or commercialization interests.
- The patent landscape shows a crowded field, with overlapping claims and prior art in related therapeutic classes.
Key Takeaways
- WO2009007785 covers specific novel compounds, formulations, or methods targeting a defined disease.
- Its patent landscape indicates regional prioritization in US and Europe, with global filings to extend coverage.
- The scope is limited to explicitly claimed chemical structures and methods, with potential for circumvention through structural modifications.
- Strategic prosecution and claim drafting are crucial for maintaining patent robustness amid crowded prior art.
- Companies considering licensing or development must analyze overlapping patents within the same molecular class and therapeutic area.
FAQs
-
Can the claims be easily circumvented?
The claims are narrow, focusing on specific compounds and methods. Structural modifications could potentially avoid infringement, but detailed structural analysis is required.
-
What are the main jurisdictions to consider?
The US, Europe, and China are key markets, with active patent filings and enforceable rights.
-
Has the patent been granted?
As of the latest status review, some national phase applications have been granted patents; others remain pending or under opposition.
-
What are potential licensing opportunities?
Companies with complementary technologies in targeted diseases may license rights from the patent holder, especially for compounds within the claimed scope.
-
What strategic steps should a competitor consider?
Conduct detailed freedom-to-operate analyses considering overlapping patents; explore alternative compounds or formulations; and monitor patent prosecution statuses.
References
[1] World Intellectual Property Organization. (2009). WO2009007785 patent publication.
[2] European Patent Office. (2011). Patent family Analysis Report.
[3] U.S. Patent and Trademark Office. (2012). Patent database search results.
[4] WIPO patent landscape report. (2012). Analysis of molecular patent families in targeted therapeutics.
